Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06241183 · ClinicalTrials.gov registry record · Phase 4
Famotidine and Antacids for Treatment of Dyspepsia
A Phase 4 study of GERD and Dyspepsia, sponsored by Stony Brook University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06241183 is a Phase 4 study of GERD and Dyspepsia that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 80 participants, below the 162-participant average among 15 other GERD trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06241183, a Phase 4 study of GERD and Dyspepsia, is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Conditions Studied
Interventions
- DRUG Intravenous Famotidine
- DRUG Oral Maalox/ Mylanta
Study Locations (1)
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06241183
The ClinicalTrials.gov registry entry for NCT06241183 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 15 other GERD trials with a reported enrollment target (51% lower). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with GERD appearing as the primary indexed condition, and to 2 interventions - of which Intravenous Famotidine is the first listed.
NCT06241183 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06241183 about?
NCT06241183 is a clinical study titled "Famotidine and Antacids for Treatment of Dyspepsia". The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is ...
What is the current status of trial NCT06241183?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2023-11-09. Estimated completion is 2025-12.
What conditions does trial NCT06241183 study?
This clinical trial studies the following conditions: GERD, Dyspepsia, Acid Reflux.
What interventions are being tested in trial NCT06241183?
The interventions under investigation include: Intravenous Famotidine (DRUG), Oral Maalox/ Mylanta (DRUG).
Who is sponsoring clinical trial NCT06241183?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06241183 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GERD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mesh Vs Pledgets for Repair of Paraesophageal Hernia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
Truncal Vagotomy in Patients Undergoing Revisional Sleeve Gastrectomy to Gastric Bypass
RECRUITING · NA
-
The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients
RECRUITING · NA
-
Mechanisms Preventing Pharyngeal Reflux
RECRUITING · NA
-
Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.